Real-world treatment patterns, healthcare resource utilization, and costs associated with high-risk endometrial cancer in England: a retrospective cohort study.

Eleanor Ralphs¹, Vimalanand S Prabhu², Erik Landfeldt³, Jess Ridsdale-Smith¹, Cheryl Teoh¹, Karen Macey⁴, Nikolay Trankov⁵, Alexandrina Lambova⁵, Jasmine Lichfield⁴, Gemma Eminowicz⁶

¹IQVIA Ltd., Real World Solutions, London, UK.

²Merck & Co., Inc., Rahway, NJ, USA.

³IQVIA, Stockholm, Sweden.

⁴MSD (UK) Limited, London, UK.

⁵IQVIA Ltd., Real World Solutions, Sofia, Bulgaria.

⁶Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK.

PubMed DOI

Abstract

OBJECTIVES: To describe real-world treatment patterns, healthcare resource utilization (HCRU), and hospital-based non-drug direct medical costs of patients with high-risk endometrial cancer (HR-EC) from initiation of first adjuvant therapy in England. METHODS: Adult women with HR-EC (i.e. stage I/II EC with non-endometrioid histology or stage III/IVa EC with any histology) who received adjuvant t…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.